The H. pylori machinery that “injects” an oncoprotein into stomach cells contributes to the development of gastric cancer, Vanderbilt researchers demonstrate.

A Vanderbilt gastroenterologist is helping lead an effort to establish screening guidelines for gastric cancer in the United States, where the number of people at risk for the cancer is increasing as the nation’s population becomes more diverse.

Timothy Cover and colleagues report new insights into the sources of energy used by a bacterial “machine” linked to the pathogenesis of stomach cancer.

VUMC researchers have created the world’s first laboratory model of precancerous changes in the lining of the stomach, a scientific tour de force that is helping to unlock the mysteries of gastric cancer development.

New research findings provide insight into the detrimental events that develop in response to H. pylori infection.

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

The immune receptor NOD1 may be a prime target for preventing or treating H. pylori infections — the most significant risk factor for stomach cancer, Vanderbilt researchers have discovered.